Centrosomes are microtubule-organizing centers that facilitate bipolar mitotic spindle assembly and chromosome segregation. Recognizing that centrosome amplification is a common feature of aneuploid cancer cells, we tested whether supernumerary centrosomes are sufficient to drive tumor development. To do this, we constructed and analyzed mice in which centrosome amplification can be induced by a Cre-recombinase-mediated increase in expression of Polo-like kinase 4 (Plk4). Elevated Plk4 in mouse fibroblasts produced supernumerary centrosomes and enhanced the expected mitotic errors, but proliferation continued only after inactivation of the p53 tumor suppressor. Increasing Plk4 levels in mice with functional p53 produced centrosome amplification in liver and skin, but this did not promote spontaneous tumor development in these tissues or enhance the growth of chemically induced skin tumors. In the absence of p53, Plk4 overexpression generated widespread centrosome amplification, but did not drive additional tumors or affect development of the fatal thymic lymphomas that arise in animals lacking p53. We conclude that, independent of p53 status, supernumerary centrosomes are not sufficient to drive tumor formation.
centrosome amplification | tumorigenesis | p53 | Plk4 kinase S ince their initial description by Theodore Boveri in 1900 (1), centrosomes have been recognized as the main microtubuleorganizing centers of animal cells and organize bipolar microtubule spindle assembly and function during mitosis. To ensure that chromosomes are divided faithfully into the two daughter cells, the number of centrosomes must be precisely controlled. Cells begin the cycle with a single centrosome that duplicates exactly once to give rise to two centrosomes that form the poles of the mitotic spindle (2, 3) . The acquisition of more than two centrosomes, a state known as centrosome amplification, can lead to chromosome segregation errors and subsequent aneuploidy (4-7). In addition, centrosome abnormalities have been proposed to lead to alterations in microtubule nucleation and organization that promote the loss of cell and tissue architecture observed in cancers. Consistent with this, recent work has shown that supernumerary centrosomes can promote cellular invasion in an in vitro model (8) .
Centrosome amplification is commonly observed in hematologic malignancies and solid tumors, and a clear link exists between centrosome amplification and aneuploidy in a wide variety of cancer cell lines (6, 7, 9, 10) . Furthermore, the presence of supernumerary centrosomes correlates with increased tumor aggressiveness and poor prognosis in human patients (11) . Experiments with transplanted larval brain and wing disk tissues in Drosophila have shown that the presence of extra centrosomes can initiate tumorigenesis with (12) or without (13, 14) driving appreciable increases in the level of aneuploidy.
Despite the strong link between centrosome amplification and tumorigenesis, extra centrosomes negatively impact the fitness of mammalian cells and tissues. Induction of centrosome amplification in nontransformed human telomerase-expressing (hTERT) RPE-1 cells triggers a p53-dependent cell cycle arrest (15) , whereas driving centrosome amplification in mice brain leads to a developmental loss of neural stem cells by p53-dependent apoptosis (16) .
More than a century ago, Boveri suggested a link between acquisition of too many centrosomes and tumorigenesis (17) . Nevertheless, whether and how centrosome amplification impacts mammalian tumor development remains untested. Here we have developed a mouse model in which centrosome amplification can be induced by Cre-recombinase-mediated elevation in Plk4 expression. In the presence of the p53 tumor suppressor, widespread elevation of Plk4 drove the production and accumulation of too many centrosomes in liver and skin cells, but this did not accelerate tumorigenesis. Chronic elevation of Plk4 levels in mice without functional p53 produced widespread accumulation of cells with centrosome amplification. Even here, however, centrosome amplification did not drive new tumors or affect the development of thymic tumors driven by loss of p53. Thus, in either the presence or the absence of p53, centrosome amplification is not a universal driver of tumor development in mammals.
Significance
Centrosomes organize the microtubule cytoskeleton in interphase and mitosis. During mitosis, the centrosomes are important for the formation and positioning of the bipolar mitotic spindle on which chromosomes are segregated. The presence of more than two centrosomes can drive mitotic chromosome segregation errors and the formation of aneuploid cells. Centrosome amplification is a common feature of aneuploid cancer cells, but a longstanding question is whether this is a cause or a consequence of tumor development. To assess this question, we generated mice in which centrosome amplification can be induced widely. Despite chronic centrosome amplification, tumorigenesis was not enhanced, demonstrating that an excess of centrosomes is not sufficient to drive tumor development. 
Results

Creation of a Mouse Model to Study the Effects of Centrosome
Amplification. Centrosome duplication is controlled by Polo-like kinase 4 (Plk4), and increased expression of Plk4 gives rise to the formation of multiple centrosomes in the same cell cycle (15, (18) (19) (20) (21) . To establish the effects of centrosome amplification in vivo, we developed a transgenic mouse line in which murine Plk4-EYFP could be conditionally increased in cells after expression of Cre recombinase (Fig. 1A) . In the absence of Cre activity, a chicken β-actin/rabbit β-globin promoter (CAG) (22) drove expression of histone H2B-mRFP, followed by a transcription termination sequence flanked by lox P sites that served to silence expression of a downstream Plk4-EYFP gene. Thus, expression of H2B-mRFP served as an initial marker for transgene expression.
Seven mice founder lines were produced. Founder line 39 was determined to have the highest level of H2B-mRFP expression and thus was selected for further characterization (hereinafter referred to as Plk4 OE) (Fig. 1B and Fig. S1A ). Immunoblotting of tissue lysates revealed H2B-mRFP expression in a wide range of tissues (Fig. 1C) . Nevertheless, immunofluorescence analysis of individual cells in tissue sections revealed wide variability in the fraction of H2B-mRFP-positive nuclei across different tissues (Fig. S1B ).
Supernumerary Centrosomes Promote Chromosome Segregation Errors
and Aneuploidy in Primary Fibroblasts. To test the ability of transgenic Plk4-EYFP to drive centrosome amplification, we derived mouse embryonic fibroblasts (MEFs) from Plk4 OE embryos. Infection of the MEFs with adenovirus encoding Cre recombinase (Ad-Cre) produced excision of the H2B-mRFP gene and activated expression of Plk4-EYFP (Fig. 1D) . At 5 d after infection, 77% of Plk4 OE cells exhibited supernumerary centrosomes ( Fig. 1 E and   F) , indicating that our transgenic model was capable of driving centrosome amplification in vitro. As expected, the extra centrosomes were functional, acting as microtubule-organizing centers during mitosis and contributing to the formation of abnormal mitotic figures (Fig. 1G and Fig. S1C ).
We next assessed whether supernumerary centrosomes where capable of promoting mitotic errors and aneuploidy in MEFs. Using populations of MEFs prepared from independent embryos carrying the Plk4 OE transgene, at 5 d after Ad-Cre transduction we analyzed metaphase chromosome spreads (Fig. 1H) , formation of micronuclei (Fig. 1I) , and number of copies of chromosome 19 in interphase nuclei (Fig. 1J) . In all three cases, there was a significant increase in mitotic errors and aneuploidy in the Ad-Cre-treated cells compared with untreated control cells, indicating that supernumerary centrosomes in MEFs derived from Plk4 OE mice can generate aneuploidy.
To evaluate the effect of the supernumerary centrosomes on mitotic chromosome segregation, we performed live imaging of skin fibroblasts expressing histone H2B-RFP and Centrin-GFP. This analysis revealed that extra centrosomes led to a threefold increase in the frequency of abnormal mitotic divisions in skin fibroblasts (75% abnormal divisions in cells with supernumerary centrosomes, compared with 25% in cells with two centrosomes) ( Fig. 2 A and E). Cells with supernumerary centrosomes showed a greater than threefold increase in lagging chromosomes and DNA bridges in anaphase ( Fig. 2 B-E). In addition, whereas multipolar divisions were absent in cells with two centrosomes, multipolar divisions were observed in 15% of mitoses in cells with supernumerary centrosomes (Fig. 2 D and E) . Taken together, these data show that supernumerary centrosomes act as microtubule nucleating centers and are competent to induce chromosome segregation errors in vitro. Plk4-Mediated Centrosome Amplification in Vivo. To drive expression of Plk4-EYFP in vivo, we crossed Plk4 OE transgenic animals to mice expressing Cre recombinase under control of the endogenous Meox-2 promoter (23) (Fig. S1D ). Meox-2-Cre is expressed from embryonic day 5 in epiblast-derived tissues. Plk4 OE;Meox2-Cre animals died shortly after birth as a result of microcephalic brain development ( Fig. S1 E and F) . A similar defect was previously observed when Plk4 was selectively overexpressed during brain development of mice (16) .
To overcome the early embryonic lethality associated with Plk4 overexpression, we took advantage of a tamoxifen inducible Cre recombinase (ERT-Cre) to induce Cre recombination in young mice (24) . We first crossed ERT-Cre mice to mice expressing a Cre-inducible β-galactosidase reporter (25) and assayed Cre activity after exposing animals to tamoxifen in their diet for 2 mo (Fig. S2 A and B) . Staining of tissue sections with X-gal revealed Cre activity in all organs examined: heart, muscle, thymus, spleen, pancreas, stomach, intestine, colon, skin, salivary glands, liver, thymus, kidney, lung, and brain (Fig. S2C ). These data demonstrate the ability to induce widespread Cre activity using tamoxifen administered through the diet.
To visualize centrosomes in tissue sections, we introduced a Rosa26-targeted, lox-STOP-lox-Centrin 1-GFP construct into Plk4 OE;ERT-Cre animals. In triply transgenic animals (Plk4 OE;ERTCre;Centrin-GFP), the action of Cre inactivates H2B-mRFP expression and activates both Plk4 and Centrin-GFP expression, the latter providing a marker to count centrosomes in cells exposed to active Cre (Fig. 3A) . We derived skin fibroblasts from Plk4 OE;ERT-Cre;Centrin-GFP mice and treated them with 4-hydroxytamoxifen (4-OHT) to assess induction of centrosome amplification. At 48 h after 4-OHT treatment, 21% of cells exhibited centrosome amplification, compared with only 2% of untreated control cells (Fig. 3 B and C) . Nevertheless, at 8 d after induction of Plk4 overexpression, the frequency of centrosome amplification had decreased to 5%, indicating a fitness disadvantage in cells with elevated Plk4 and supernumerary centrosomes (Fig. 3C) . Consistently, fibroblasts with extra centrosomes showed a reduced proliferation rate and clonogenic survival compared with untreated control cells (Fig. 3 D and E) .
Overexpression of Plk4 in the liver produced a more than twofold elevation of centrosome amplification (to 47%) compared with the basal level observed in control animals not bearing the Plk4 transgene (22%) (Fig. 3 I and J) . Similarly, an increase in Plk4 RNA drove centrosome amplification in 20% of keratinocytes within the skin epidermis (26) . However, despite 4-fold and 30-fold elevations, respectively, in the level of Plk4 transcripts in lung and kidney ( Fig. 3F and Fig. S2D ), cells in either tissue did not accumulate supernumerary centrosomes above the proportion found in control animals ( Fig. 3 G and H and Fig. S2 E  and F) . Similarly, no overt centrosome amplification was observed in the spleen and pancreas. Thus, in mice with active p53, Cre-mediated activation of Plk4 overexpression is sufficient to drive centrosome amplification in permissive tissues, including the liver (Fig. 3) and skin (26) . Nevertheless, cohorts of Plk4-overexpressing mice showed no difference in overall survival compared with control animals (Fig. 3K) . Centrosomes. Previous studies have implicated the existence of one or more p53-dependent pathways that prevent the proliferation of cells with supernumerary centrosomes both in cell culture (15) and in the mouse brain (16) . To test whether p53 is responsible for eliminating cells that acquire extra centrosomes, we introduced a conditional allele of p53 into Plk4 OE mice (27) . Quadruply modified animals (Plk4 OE;ERT-Cre;Centrin-GFP;p53 f/+ ) were created harboring Plk4 OE, ERT-Cre, conditional Centrin 1-GFP, one conditional (floxed) p53 allele, and one wild type (WT) p53 allele (Fig. 4A) . Thus, Cre induction will activate the Plk4 and Centrin f/+ mice and in control ERT-Cre;Centrin-GFP;p53 f/+ mice. Measurements were taken at 2 mo after tamoxifen treatment. Bars represent the mean, and error bars indicate SEM. n = 6 mice with Plk4 OE activation and n = 6 without Plk4 OE activation. ns, P > 0.05; P value of unpaired t test calculated on the mean values from six independent measurements. A minimum of 177 centrin-positive cells were counted for each animal. (C) Tumor-free survival of Plk4 OE; ERT-Cre;Centrin-GFP;p53 f/+ mice and control ERT-Cre;Centrin-GFP;p53 f/+ mice after 2 mo of tamoxifen treatment. n = 15 mice with tamoxifen treatment and n = 9 without tamoxifen treatment. (D) Fold change in Plk4 mRNA in kidneys of Plk4 OE; ERT-Cre;Centrin-GFP;p53 f/f mice compared with control ERT-Cre;Centrin-GFP;p53 f/f mice. Measurements were taken at 2 mo after tamoxifen treatment. Bars represent the mean, and error bars indicate SEM. n = 6 mice for tamoxifen-induced and n = 4 for uninduced. *P < 0.05; P value of unpaired t test calculated on the mean values from four and six independent measurements. (E) Representative immunofluorescence image of a kidney section (a glomerulus is visible in the middle of the image) from a Plk4 OE; ERT-Cre; Centrin-GFP;p53 f/f mouse after tamoxifen treatment. (F) Percentage of centrosome amplification within cells expressing Centrin-GFP in the kidney of Plk4 OE; ERT-Cre;Centrin-GFP;p53 f/f mice and in control ERT-Cre;Centrin-GFP;p53 f/f mice. Measurements were taken two months after tamoxifen treatment. Bars represent the mean, and error bars indicate SEM. n = 6 mice with Plk4 OE and n = 4 controls. *P < 0.05; P value of unpaired t test calculated on the mean values from four and six independent measurements. A minimum of 172 centrin-positive cells were counted for each animal. f/f mice after tamoxifen induction of Cre to activate the Plk4 OE gene and inactivate p53. Red arrowheads point to segregation errors. The graph shows the proportion of abnormal anaphases (lagging chromosomes, chromosome bridges, and multipolar anaphases). Bars show the mean and error bars show the SEM from measurements from six individual tumors for each condition. ***P < 0.001; P value of an unpaired t test calculated on the mean values of measurements from six independent tumors. A total of 107 anaphases were analyzed for the control condition, and 121 anaphases were analyzed for the Plk4 OE condition.
1-GFP transgenes while simultaneously inactivating one allele of p53. Consequently, GFP-positive centrosomes mark cells with successful induction of Cre and in which both increased Plk4 levels and reduced p53 expression are expected.
Using these Plk4 OE;ERT-Cre;Centrin-GFP;p53 f/+ mice, we first tested whether centrosome amplification was tolerated in p53 heterozygous cells. Cre-dependent Plk4 overexpression and inactivation of the floxed p53 allele in Plk4 OE;ERT-Cre;Centrin-GFP;p53 f/+ skin fibroblasts promoted centrosome amplification, with almost one-half (∼43%) of the cells accumulating more than two centrosomes by 2 d after tamoxifen treatment (Fig. 4B) . Heterozygosity for p53 allowed the continued growth of Plk4 OE cells with extra centrosomes in vitro (Fig. 4C ) and rescued their ability to form colonies in long-term growth assays (Fig. 4D) . The continued cell cycling of cells with extra centrosomes following the inactivation of one p53 allele suggests that supernumerary centrosomes promote chromosome segregation errors that enable the loss of heterozygosity of the remaining WT p53 allele.
We next tested how complete p53 loss affected cells with Plk4-driven supernumerary centrosomes. For this, ERT-Cre was used to inactivate p53 in p53 f/f skin fibroblasts also carrying Cre-activatable Plk4 OE and Centrin 1-GFP genes (Plk4 OE;ERT-Cre;Centrin-GFP;p53 f/f ). As expected based on previous work (28), increased Plk4 levels augmented centrosome amplification in fibroblasts lacking p53: 54% of cells contained more than two centrosomes within 2 d of Plk4 induction (Fig. 4E) , compared with 34% in p53 null fibroblasts without Plk4 overexpression and 9% in WT fibroblasts. Importantly, p53 null fibroblasts with a Plk4-dependent elevation in extra centrosomes proliferated at a similar rate to that of control cells lacking p53 (Fig. 3F) , and the clonogenic survival of cells with supernumerary centrosomes was enhanced by loss of p53 (Fig. 4G) . We conclude that p53 suppresses the maintenance and proliferation of cells with supernumerary centrosomes in vitro.
Plk4-Driven Centrosome Amplification Does Not Affect Tumorigenesis in p53 Heterozygous Mice. To assess whether centrosome amplification affected tumor development in mice with reduced levels of p53, we assembled cohorts of Plk4 OE mice with ERT-Cre, conditional Centrin 1-GFP, and one conditional p53 allele (p53 f/+ ). Mice were fed for 2 mo with tamoxifen to activate the Plk4 and Centrin 1-GFP genes while inactivating p53 (Fig. S2A) . Despite the fact that loss of a single allele of p53 permitted the growth of cells with supernumerary centrosomes in vitro (Fig. 4 C and D) , Plk4 overexpression did not alter centrosome numbers in the cells in the lung and kidney of p53 +/− mice ( Fig. 5 A and B and Fig. S3 A and B), consistent with continuing p53-dependent arrest and/or death of cells that underwent aberrant mitosis with too many centrosomes.
p53 heterozygous animals develop an increased frequency of a variety of tumor types, typically accompanied by loss of heterozygosity for p53 (29) (30) (31) . To determine whether Plk4 overexpression and resultant centrosome amplification influenced tumor development in p53 heterozygous mice, we fed Plk4 OE;ERT-Cre; Centrin-GFP;p53 f/+ mice tamoxifen for 2 mo starting at weaning. The resultant Plk4 overexpression, including in lung and kidney, had no effect on tumor initiation or tumor-free survival (Fig. 5C ) and the spectrum of tumors that formed was similar to that found in mice heterozygous for p53 (Fig. S3 C and D) .
Plk4-Driven Centrosome Amplification Does Not Affect Tumorigenesis in p53 Null Mice. To assess whether Plk4-dependent centrosome amplification affects tumor development in the absence of p53, we assembled cohorts of mice possessing ERT-Cre, the conditional Plk4 OE, conditional Centrin 1-GFP, and two conditional p53 alleles (i.e., p53 f/f ). Centrosome number was analyzed in mice fed for 2 mo with tamoxifen to activate the Plk4 and Centrin-GFP genes and inactivate both p53 alleles (Fig. S2A) . Plk4 mRNA levels were strongly increased (by 16-and 48-fold, respectively) in the lung and kidney of tamoxifen-fed Plk4 OE;ERT-Cre;Centrin-GFP; p53 f/f animals ( Fig. 5 D and Fig. S3E ). Importantly, cells with centrosome amplification were increased fourfold in lung and fivefold in kidney in these mice Fig. 5 E and F and (Fig. S3 F and G) .
As expected from the high penetrance of thymic lymphomas reported previously in a different p53 null mouse (31), tamoxifeninduced Cre expression in p53 f/f animals led to the development of fatal thymic lymphomas (Fig. S3H ) starting at 144 d of age and occurring with complete penetrance by 235 d (Fig. 5G) . Induction of Cre to both activate the Plk4 OE transgene and inactivate the p53 f/f alleles also produced lymphomas in 100% of the animals, with an onset and overall survival time identical to those seen in p53 null mice without Plk4 overexpression (produced by tamoxifen-induction of Cre in ERT-Cre;Centrin-GFP;p53 f/f mice) (Fig. 5G) .
Cre-dependent activation of the conditional Centrin 1-GFP transgene was used to mark centrosomes in cells in which p53 was inactivated. A striking heterogeneity was observed in the fraction of cells with Centrin 1-GFP-positive centrosomes in thymic tumors from both p53 f/f and Plk4 OE;p53 f/f mice (from ∼2% to ∼90%) (Fig. S3I) . This heterogeneity was mimicked by a similar divergence in the level of centrosome amplification (between ∼1% and 30%) in the tumors from p53 f/f or Plk4 OE;p53 f/f mice (Fig. 5H) . Plk4 OE-induced centrosome amplification promoted increased genetic instability, as demonstrated by a significant increase in the frequency of abnormal anaphases in the tumors from Plk4 OE mice (elevated from 50.4% in p53 f/f to 69% in Plk4 OE;p53 f/f ; P < 0.0001, t test with six control tumors and six Plk4 OE tumors) (Fig. 5I) . Thus, Plk4-driven centrosome amplification can drive increased genetic instability in p53 null thymic tumors, but this does not reduce (or extend) tumor-free survival from loss of p53 or enhance thymic tumor initiation and growth.
Centrosome Amplification and Induced Tumorigenesis in Skin. Recognizing that >10% of basal epidermal cells of the skin have extra centrosomes throughout adult life when Plk4 overexpression is induced in those cells (26), we tested whether centrosome amplification influenced tumor development in a classical skin carcinogenesis model in which topical application of the chemical mutagen 7,12-dimethylbenz(a)anthracene (DMBA) is followed by multiple applications of the tumor-promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) (32) (Fig. 6A) . Treatment with DMBA/ TPA induces papillomas, a proportion of which can progress into squamous cell carcinomas.
To achieve Plk4 overexpression uniquely in the epidermis, Plk4 OE mice were crossed to animals expressing Cre under control of the keratin 14 promoter (K14-Cre) (33) . A DMBA/TPA treatment protocol was applied to the right side of the back skin in a cohort of Plk4 OE;K14-Cre and control (Plk4 OE, K14-Cre, and WT) mice, and tumor development was followed over time. Initial analysis confirmed that skin epidermis was permissive for centrosome amplification in the presence of active p53 (Fig. 6 E and F), with >20% of cells containing more than two centrosomes in the Plk4 OE;K14-Cre mice. The median tumor-free survival for Plk4 OE;K14-Cre (n = 23) and control animals (n = 62) was indistinguishable, however (Fig. 6B) .
Both cohorts developed similar numbers of tumors per animal, with the Plk4 OE;K14-Cre mice exhibiting a statistically insignificant trend toward lower overall tumor volume per mouse (Fig. 6 C and  D) . At no point did animals develop tumors on the untreated left side of the back. Analysis of cells within the tumors revealed cells with extra centrosomes at comparable percentages to those measured in newborns ( Fig. 6 E and F) . Given the lack of change in overall or tumor-free survival in Plk4 OE;K14-Cre and control mice (26), we conclude that centrosome amplification in the skin does not enhance chemical carcinogenesis-induced tumorigenesis or spontaneous tumorigenesis during aging.
Discussion
Centrosome amplification has been observed in a wide array of human tumors (9, 11, (34) (35) (36) and is capable of promoting chromosomal instability and aneuploidy both in vitro (6, 7) and in vivo (12, 16) . These observations have promoted the idea that abnormalities in centrosome number may drive events in tumor development. Here we have tested this proposal using a mouse model in which the levels of Plk4 can be conditionally increased to drive centrosome amplification in vivo. Our data reveal that despite widespread Plk4 elevation, p53 acts to prevent accumulation of cells with extra centrosomes in most tissues of the mouse. Chronic Plk4 elevation did not increase spontaneous tumors during aging in either p53 +/+ or p53 +/− mice. This held true even in the few permissive tissues, including the liver and the proliferative basal layer of the skin epidermis, in which cells with amplified centrosomes did accumulate after Plk4 overexpression. In addition, chronic elevation of Plk4 and centrosome number in p53 null mice did not affect the development and timing of lethal thymic lymphomas or promote development of other tumor types within the restricted lifespan of p53 −/− mice. Taken together, our evidence establishes that centrosome amplification is not sufficient to drive tumor formation in mammals, with or without active p53.
Both centrosome amplification (37, 38) and centrosome loss (39, 40) have previously been reported to lead to a p53-dependent cell cycle arrest in skin fibroblasts. Centrosome amplification is also selected against during brain development in mice (16) and in Drosophila (12) . Adding to this knowledge, we now show that p53 prevents widespread centrosome amplification in many tissue types in mice (Fig. 5) . It remains to be determined whether p53 directly controls centrosome duplication or rather acts to block the proliferation of cells that spontaneously accumulate extra centrosomes through errors in centrosome duplication or failure of cytokinesis.
We found that increased Plk4 levels exacerbated centrosome amplification in mice lacking p53, but failed to influence the development of thymic lymphomas that occur with complete penetrance in the absence of p53 (Fig. 5) . The level of centrosome amplification in the thymic lymphomas varied widely but, surprisingly, was not increased in the Plk4 OE mice. This finding suggests that excessive levels of centrosome amplification were selected against during the evolution of these tumors. To avoid the highly aggressive thymic lymphomas that develop in the absence of p53 activity while maintaining sustained levels of centrosome amplification in multiple tissues of adult mice, an attractive future approach would be to analyze athymic Plk4 OE;p53 −/− mice (e.g., after surgical thymectomy in young mice) or to combine the Plk4 OE;p53
f/f mouse model with tissue-specific expression of Cre to induce Plk4 overexpression and inactivation of p53.
Plk4 overexpression drove the formation of supernumerary centrosomes in the skin and liver of mice, indicating that these tissues tolerate centrosome amplification even in the presence of active p53. Nevertheless, increased centrosome numbers did not promote spontaneous tumor development in these tissues. Furthermore, although loss of the remaining WT allele of p53 will drive the development of a variety of tumors in aging p53 +/− animals (29-31), surprisingly, centrosome amplification in the liver and skin did not alter tumor development in p53 +/− animals. We note that in addition to its tolerance for centrosome amplification in p53 competent mice, the mouse livers displayed variable and evolving levels of polyploidy (41) . Thus, a parallel can be drawn between hepatocytes that can naturally acquire extra centrosomes by failing one or more cytokinesis but still maintain proliferative capabilities and cancer cells with extra centrosomes that are frequently tetraploid or hypertriploid (42, 43) . Despite the absence of tumor formation in the livers of p53 +/− animals in our in vivo system, the idea of tetraploidization as an intermediate in cell transformation and tumor initiation has been proposed and tested in different in vitro systems (44, 45) . The recent development of a mouse in which cytokinesis failure can be experimentally triggered in skin fibroblasts in vivo (46) potentially could allow testing of acute Plk4-driven centrosome amplification combined with cytokinesis failure as a means to test whether elevated centrosome amplification can favor tumor development in induced tetraploid cells.
Our results in a mammalian organism contrast with what has been reported in flies, in which chronic overexpression of SAK, the fly homolog of Plk4, generated cells with extra centrosomes that were capable of forming tumors when transplanted into WT hosts (12, 14) . The mechanistic determinants for the differing outcomes between the mammalian and insect examples have not been established. One potential explanation for the difference is that to suppress tumorigenesis and support the much longer mammalian life span, cell growth control is substantially more stringent in mammals than in flies.
Beyond our analysis of how centrosome amplification affects spontaneous tumorigenesis during aging or from loss of the p53 tumor suppressor, we also tested how similar amplification affected DMBA/TPA-induced papillomas that arise from cell proliferation in the presence of an induced Ras mutation (32) . We found that chronic increase in centrosome number did not affect the number of lesions or promote an increase in tumor volume. Recognizing that extra centrosomes have been reported to promote cellular invasion in vitro (8), we then examined invasion of the basement membrane of the epidermis, the initial step in metastasis to other organs. We found no increase in invasive behavior in papillomas with Plk4-driven centrosome amplification, and no change in the rate at which these papillomas progressed into aggressive squamous cell carcinomas. Given that loss of the p19
Arf tumor suppressor has been shown to stimulate papilloma transition to squamous cell carcinomas and their metastatic capabilities (47) , an examination of the invasion potential of papillomas with p19
Arf deficiency and induced centrosome amplification is warranted.
The experimental approaches used here exploited conditional elevation of Plk4 expression to drive what is expected to be continuing centrosome amplification. It is possible that a continuing excess of centrosomes produces a level of genome instability that suppresses any initial increase in tumorigenic potential arising from increased chromosome segregation errors. Therefore, analyzing the correlation between the levels of induced centrosome amplification and the extent of the resulting aneuploidy would be a valuable test for assessing the sensitivity of different tissues to centrosome amplification-driven aneuploidy. We note, however, that even in the current tests, centrosome amplification would be expected to be transient in at least a proportion of cells in which a mitotic chromosome segregation error included loss of the chromosome carrying the Plk4 OE transgene. We suggest that a future, more comprehensive test of whether (and/or how) transiently induced centrosome amplification affects tumorigenesis would be of great interest. Nevertheless, our current evidence demonstrates that chronic centrosome amplification is not sufficient to drive tumor formation in mammals independent of p53 status.
Experimental Procedures
Animals. Transgenic mice bearing the conditional Plk4 transgene were generated by injecting the construct shown in Fig. 1A into the pronucleus of C57BL/6 fertilized eggs. Mice were subsequently backcrossed onto a C57BL/6 background. To generate Cre-inducible Centrin 1-GFP mice, a lox-STOP-lox-Centrin 1-GFP cassette was targeted to the ROSA26 locus under control of the endogenous ROSA26 promoter in 129 × 1/SvJ ES cells. Resulting mice were backcrossed onto a C57 Bl/6 background. Meox2-Cre and ERT-Cre mice were obtained from JAX mice (ref. #003755 and #004682, respectively) on C57BL/6 congenic background. The tamoxifen citrate diet was prepared by adding 5 g of tamoxifen citrate (TCI America) and 620 g of sucrose to 12 kg of standard diet base (Teklad Global 2016; Harlan Laboratories). Mice were housed and cared for in an Association for the Assessment and Accreditation of Laboratory Animal Care-accredited facility, and all animal experiments were conducted in accordance with Institutional Animal Care and Use Committee-approved protocols. Inquiries concerning Centrin1-GFP mice should be directed to S.M.E. (syevans@ucsd.edu).
